Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Harmony Biosciences Holdings, Inc. has 58.12M shares outstanding.

As of June 30, 2026, Harmony Biosciences Holdings, Inc. maintains a current ratio of 3.48, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.41, indicating elevated leverage, while an interest coverage ratio of 19.00 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Harmony Biosciences Holdings, Inc. posted a return on equity (ROE) of 20.46, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.52 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.61, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 18.24, useful for judging operating efficiency across full business cycles. The company generates approximately 58.49M in revenue per employee across its workforce of 286.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 37.87 indicates how many times Harmony Biosciences Holdings, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Harmony Biosciences Holdings, Inc. recorded 1.05B in income tax expense. That works out to an effective tax rate of 24.85, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.21B, leaving 3.17B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Harmony Biosciences Holdings, Inc. generated 16.77B in revenue and converted that into 3.17B in net income, yielding earnings per share of 53.92. EBITDA reached 4.47B, while operating income came in at 4.03B.

As of June 30, 2026, Harmony Biosciences Holdings, Inc. holds 11.67B in cash and equivalents against 2.69B in total debt, resulting in a net debt position of -6.92B. Total book value stands at 17.46B, with working capital of 10.14B providing operational flexibility.

Harmony Biosciences Holdings, Inc. produced 6.20B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.11M in capital expenditures, free cash flow totaled 6.20B - equivalent to 107.40 per share.

Over the twelve months ended June 30, 2026, Harmony Biosciences Holdings, Inc. posted a gross margin of 75.42, reflecting its pricing power and cost economics. The operating margin of 24.03 and net profit margin of 18.88 provide insight into operational efficiency.